domain of the Peyronie's Disease Questionnaire (PDQ) and were scored on a scale of 0-16 before, during and after treatment.
INTRODUCTION AND OBJECTIVES: Patients affected by
Peyronie's disease (PD) benefit most from therapy with Collagenase Clostridium Hystolyticum (CCH). However, clinical results in patients with uncommon penile curvature (PC) have been never reported.
METHODS: We retrospectively collected data of patients affected by ventrolateral PC secondary to PD. Patients received pharmacologically induced artificial erection test (intra-cavernous injection) to assess the degree of penile curvature (PC) at baseline and after the completion of the treatment. All patients underwent a modified treatment protocol, which consisted of 3 intra-lesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum curvature. After each injection, patients were instructed to follow a strict routine involving daily penile stretching in the intervals between injections. As previous reported, success of therapy was defined as a decrease in PC of ! 20 from baseline (Cocci et al. BJU Int 2018) . RESULTS: A total of 65 patients were included in the analysis. Median age was 59.0 years (IQR 53.00-63.0), median curvature was 40.0 and median duration of the disease was 12.0 years (IQR 6.5-24.0). 53 patients had ventral PC (81.54%), 7 has hourglass PC (10.77%) and 5 has shortening PC (7.69%). Median changes of PC were -20.0 p<0.01) in ventral PC, 0.0; p<0.01) . At one-way ANOVA test, we did not find significant differences between groups. The rate of PC success was 56.6% (30/23) in ventral PC, 57.14% (4/3) in hourglass and 20% (1/4) (p[0.29). Treatment success was not influenced by characteristics of curvature (OR[ 0.66; p[0.20) .
CONCLUSIONS: CCH injection treatment has proven to be effective in the improvement of PC in case of uncommon curvatures, including ventrolateral, shortening and hourglass deformities.
Source of Funding: None

MP65-10 COMPARISON OF STANDARDIZED INTRALESIONAL INJECTION OF INTERFERON 2-ALPHA-2B (IFN) AND COLLAGENASE CLOSTRIDIUM HISTOLYTICIUM (CCH) FOR PEYRONIE'S DISEASE (PD) AT SINGLE HEALTH CENTER
Kyle Gillis*, Portland, OR; Ashley Winter, Clackamas, OR INTRODUCTION AND OBJECTIVES: Utilization of intralesional therapy for the treatment of PD has increased dramatically since FDA approval of CCH for this indication in 2013. This poses a significant economic burden to healthcare systems due to pharmaceutical costs. Intralesional injection of both CCH and IFN are recommended according to AUA guidelines. Previous literature comparing CCH and IFN demonstrated similar efficacy, though in a non-standardized fashion across multiple medical centers. The goal of this actively enrolling study is to compare clinical outcomes for intralesional injections of CCH and a lower-cost alternative, IFN, in a standardized fashion at a single health organization.
METHODS: Patients with PD were offered both intralesional options, unless contraindicated, for noncalcified stable penile lesions inducing curvature between 30 to 90 degrees. Injections were conducted in a standardized fashion with a cycle of two intralesional injections 24-72 hours apart according to the single-puncture protocol into the plaque at site of maximal concavity followed by daily at-home modeling. This cycle was repeated for up to four iterations, 6-7 weeks apart. Curvature was measured on the first day of each cycle with a pharmacologic erection. IFN injections consisted of 0.25 mL, 2.5 million IU while CCH included 0.58 mg. Clinical outcomes were measured in prospective fashion.
RESULTS: Seventeen men with PD were acceptable intralesional candidates and met study inclusion criteria. Six men opted for CCH, 11 for IFN injections. All patients had a dorsal plaques resulting in baseline curvature of 45 to 90 , mean 57 . IFN patients had a baseline curvature between 37-85 , mean 55.6 . CCH cohort had a baseline between 45-90 with a mean of 61.2 , p[ 0.48). The IFN cohort received 31 injections (mean 2.8 injection/patient) for a list cost of $5,301 while 11 CCH injections (mean 1.8) for a cost of $51,678. Ten of the 11 men demonstrated improvement of penile curvature, overall mean 12.6 or 23% improvement from baseline deformity. Patients treated with CCH had a modest improvement of 3 degrees or 8% improvement. IFN patients had a modest improvement in Sexual Health Inventory for Men (SHIM) scores (mean 1.3) across treatment sessions while SHIM scores decreased for CCH patients (mean -8.2). Similarly, patients treated with IFN had a decline in Peyronie's Disease Questionaire (PQD) bother score (3.05), while CCH patients remained stable (-0.25). There were no significant complications in either treatment arm.
CONCLUSIONS: Intralesional IFN is a viable option at a fraction of the cost compared to CCH. This is the first study to compare intralesional injection of IFN and CCH in a standardized fashion at a single institution.
Source of Funding: none
MP65-11
EFFECT OF LOW-DOSE PDE5I AND LOW-ENERGY SHOCK WAVE ON ACUTE PHASE OF PEYRONIE DISEASE Mujun Lu*, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: To investigate the efficacy and safety of low-dose PDE5i and low-energy shock wave (Li-SWT) in the treatment of acute phase of Peyronie disease (PD).
METHODS: Twenty patients with acute PD within 6 month onset were collected. The patients were 26-52 years old with an average of 41.6 years. The patients were randomly divided into two groups, 12 of which were orally administered with 5 mg of tadalafil every night for 3 months; the other 8 received 4 times of Li-SWT.
Li-SWT uses the Renova shock wave therapy device with an energy density of 0.09mJ/mm2, each time 3200 times in the penile Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e953
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